Weekly Recap: Q3 loss, cash runway and Gemini study CRO selection
Lesedauer weniger als 1 min
Revelation Biosciences, Inc. (NASDAQ:REVB) reported a third-quarter 2026 net loss of $3.3 million, or $5.92 per share, and no revenue; cash fell to $9.1 million, expected to last into the second quarter of 2027. The company selected a contract research organization for its planned Gemini study in acute kidney injury.
Previous Week Recap
- Q3 Loss And Cash Runway: REVB reported a $3.3 million third-quarter 2026 net loss, or $5.92 per share, with no revenue. Cash fell to $9.1 million by Sept. 30; funds are expected to last into Q2 2027. 3 Quellen
- CRO Selected For Gemini Study: Revelation Biosciences, Inc. (REVB) selected a contract research organization for its planned Gemini study in acute kidney injury and incurred related preparation costs during the quarter. Reuters
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.